Stock Analysis
Penumbra, Inc. (PEN) Stock Analysis
Penumbra, Inc. (PEN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Penumbra, Inc. (PEN) currently has an AIQ Score of 66/100, indicating a bullish setup. Risk is the strongest factor at 92/100. Value is the weakest current factor at 48/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PEN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $320.60 |
| AIQ Score | 66/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $12.64B |
| P/E Ratio (TTM) | 79.98 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $1.07 |
| Revenue (Q3 FY2026) | $410.15M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.19 |
| Volume | 214.39K |
| 52-week range | $274.20-$362.41 |
| RSI 14 | 49.51 |
| 50-Day SMA | $320.15 |
| 200-Day SMA | $325.71 |
| Analyst Price Target | — |
| Next Earnings | Feb 24, 2027 |
PENPenumbra, Inc.
Healthcare / Medical - Devices
Leader
Strong Relative Position
Latest quote
- Momentum56
- Value48
- Quality78
- Risk resilience92
- Sentiment—
PEN Stock Analysis Summary
Penumbra, Inc. (PEN) currently has an AIQ Score of 66/100, indicating a bullish setup. Risk resilience is the strongest factor at 92/100. Value is the weakest current factor at 48/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, PEN has AIQ Score of 66/100 with Risk resilience base of 92/100 and fading Value at 48/100. Wait for component alignment before adding exposure.
Risk resilience (92/100) leads while Value (48/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.47% stock move · PEN classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PEN Bullish or Bearish Right Now?
PEN currently has a bullish overall setup. Risk Resilience is the strongest factor at 92/100, while Value is weakest at 48/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 78/100.
- - Risk Resilience is supportive at 92/100.
- - Price is +0.24% above its 50-day SMA.
- - Value is the current constraint at 48/100.
- - Price is -1.47% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (12 vs 11).
Current Consensus
PEN's Technical Analysis Consensus is currently Neutral, with 11 buy, 23 neutral, and 12 sell votes. PEN's 14-day RSI is 49.51, which places the stock in a neutral momentum range. PEN's beta is 0.19, indicating lower market sensitivity than the broad market.
What Changed in PEN?
The largest recent change in PEN is AIQ Score moving up by 0.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the PEN Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PEN Decision Framework
Public evidence layers, setup checks, and risk context for Penumbra, Inc..
Penumbra, Inc. (PEN) Stock Analysis
Penumbra, Inc. has an AIQ Score of 66/100 in a Bullish regime. Risk is strongest at 92/100. Beta is 0.19, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PEN is in a Bullish AIQ regime with score 66/100. |
| Signal Conflict | The primary conflict is that risk leads at 92/100 while value lags at 48/100. |
| Factor Evidence | Momentum 56/100 · Value 48/100 · Quality 78/100 · Risk 92/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 92/100.
Momentum is 56/100 and RSI (14) is 49.5.
PEN is in a Bullish regime at 66/100.
Risk factor is 92/100 with beta 0.19 and annual volatility 19.46%.
Current conflict: risk leads at 92/100 while value lags at 48/100.
PEN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PEN Fundamentals
PEN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PEN Technical Analysis
PEN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PEN Stock Catalysts
Track PEN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PEN Dividend Analysis
PEN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PEN Financial Data
PEN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PEN Risk Analysis
PEN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PEN Stock News
PEN stock news, market tone, recent headlines, and catalyst context.
PEN vs Medical - Devices Peers
Current peer cohort: PEN · PHG · PRCT · SNN · TNDM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PEN Current stock | 66/100 | 48/100 | 56/100 | 92/100 | 0.62 | 19.46% | Current |
| PHG Koninklijke Philips N.V. | 72/100 | 80/100 | 72/100 | 73/100 | 0.18 | 29.69% | PEN vs PHG |
| PRCT PROCEPT BioRobotics Corporation | 49/100 | 38/100 | 60/100 | 45/100 | -0.11 | 65.89% | PEN vs PRCT |
| SNN Smith & Nephew plc | 70/100 | 79/100 | 60/100 | 75/100 | -0.2 | 27.30% | PEN vs SNN |
| TNDM Tandem Diabetes Care, Inc. | 55/100 | 64/100 | 59/100 | 38/100 | 0.49 | 75.74% | PEN vs TNDM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PEN: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PEN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PEN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PEN Stock FAQ
What is PEN stock price today?
Penumbra, Inc.'s current stock price is $320.60. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PEN bullish or bearish right now?
PEN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PEN's market cap?
PEN's market cap is $12.64B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PEN's current P/E ratio?
PEN's current P/E ratio is 79.98 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PEN's RSI?
PEN's 14-day RSI is 49.51 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PEN above its 50-day and 200-day moving averages?
PEN is 0.24% from its 50-day SMA and -1.47% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PEN's next earnings date?
PEN's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PEN pay a dividend?
PEN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.